Relationship of catechol-O-methyltransferase to schizophrenia and its correlates: Evidence for associations and complex interactions

Harvard Review of Psychiatry

Volumn 15, Issue 5, 2007, Pages 233-244

  Lewandowski, Kathryn E ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Cognitive; COMT; Endophenotype; Factors; Schizophrenia; Schizotypy

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE;

BIPOLAR DISORDER; CHROMOSOME 22Q; CHROMOSOME DELETION; CINGULATE GYRUS; CORRELATION ANALYSIS; DIGEORGE SYNDROME; ENZYME ACTIVITY; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; NEUROIMAGING; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SYMPTOM; THALAMUS;

CATECHOL O-METHYLTRANSFERASE; COGNITION; DOPAMINE; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 35048842703     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220701650409     Document Type: Review

References (128)

1. Avramopoulos D, Stefanis NC, Hantoumi I, Smyrnis N, Evdokimidis I, Stefanis CN. Higher scores of self reported schizotypy in healthy young males carrying the COMT high activity allele. Mol Psychiatry 2002;7:706-11.
2. Bearden CE, Jawad AF, Lynch DR, et al. Effects of COMT genotype on behavioral symptomatology in the 22q11.2 deletion syndrome. Child Neuropsychol 2005;11:1-9.
3. Bearden CE, Jawad AF, Lynch DR, et al. Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome. Am J Psychiatry 2004;161:700-2.
4. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-22.
5. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol-O-methyltransferase gene polymorphism and schizophrenia: meta-anaysis of case-control and family-based studies. Am J Psychiatry 2003;60:469-76.
6. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:651-4.
7. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methultransferase gene to 22q11.1-q11.2. Genomics 1992;12:822-5.
8. Williams HJ, Owen MJ, O'donovan MC. Is COMT a susceptibility gene for schizophrenia? Schizophr Bull 2007;33:635-41.
9. Gottesman II. Schizophrenia genesis: the origins of madness. San Francisco: Freeman, 1991.
10. Tsuang MT, Faraone SV. Schizophrenia: epidemiology and genetic studies. IJP Psychiat Behav Sci 1998;8:59-71.
11. Andreasen, NC. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. Arch Gen Psychiatry 1999;56:781-7.
12. Keshavan MS. Neurodevelopment and schizophrenia: quo vadis? In: Keshavan MS, Murray RM, eds. Neurodevelopment and adult psychopathology. London: Cambridge University Press, 1997:267-77.
13. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
14. Meehl PE. Schizotaxia, schizotypy, schizophrenia. Am Psychol 1962;17:827-38.
15. Meehl PE. Toward an integrated theory of schizotaxia, schizotypy, and schizophrenia. J Personal Disord 1990;4:1-99.
16. Tsuang MT, Stone WS, Faraone SV. Toward reformulating the diagnosis of schizophrenia. Am J Psychiatry 2000;157:1041-50.
17. Gooding DC, Iacono WG. Schizophrenia through the lens of a developmental psychopathology perspective. In: Cohen DJ, Cicchetti D, eds. Developmental psychopathology. New York: John Wiley & Sons, 1995:535-80.
18. Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 1958;233:702-5.
19. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994;63:972-9.
20. Graf WD, Unis AS, Yates CM, et al. Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 2001;57:410-6.
21. Lachman HM, Morrow B, Shprintzen R, et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velocardio-facial syndrome. Am J Med Genet 1996;67:468-72.
22. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807-21.
23. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999;39:19-52.
24. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 1998;18:2697-708.
25. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-o- methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 2004;24:5331-5.
26. Bruder TE, Keilp JG, Xu H, et al. Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry 2005;58:901-7.
27. Bleuler EP; Zinkin J, trans. Dementia praecox or the group of schizophrenias. New York: International Universities Press, 1950 [originally published 1911].
28. Kraepelin E. Dementia praecox and paraphrenia. Edinburgh, Scotland: Livingstone, 1919 [originally published 1913].
29. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004;7(suppl 1):S1-5.
30. Weinberger DR, Egan MF, Bertolino A, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-44.
31. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006;39(suppl 1):S10-4.
32. Swerdlow NR, Lipska BK, Weinberger DR, Braff DL, Jaskiw GE, Geyer MA. Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology 1995;122:27-34.
33. Flagstad P, Mork A, Glenthoj BY, Van Beek J, Michael-Titus AT, Didriksen M. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology 2004;29:2052-64.
34. Kolachana BS, Saunders RC, Weinberger DR. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience 1995;69:859-68.
35. Bertolino A, Breier A, Callicott JH, et al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000;22:125-32.
36. Abbott C, Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr Opin Psychiatry 2006;19:135-9.
37. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
38. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test manual, revised and expanded. Odessa, FL: Psychological Assessment Resources, 1993.
39. Bertolino A, Roffman JL, Lipska BK, van Gelderen P, Olson A, Weinberger DR. Reduced N-Acetylaspartate in prefrontal cortex of adult rats with neonatal hippocampal damage. Cereb Cortex 2002;12:983-90.
40. Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. Philos Trans R Soc Lond B Biol Sci 1996;351:1483-93.
41. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci 2004;8:325-35.
42. Bilder RM, Bolabka J, Czobor P, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002;52:701-7.
43. Goldberg TE, Egan MF, Gscheidle T, et al. Executive sub-processes in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003;60:889-96.
44. Han DH, Kee BS, Min KJ, et al. Effects of catechol-O-methyltransferase Val158Met polymorphism on the cognitive stability and aggression in the first-onset schizophrenic patients. Neuroreport 2006;17:95-9.
45. Ehlis AC, Reif A, Herrmann MJ, Lesch KP, Fallgatter AJ. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology 2007;32:162-70.
46. Galderisi S, Maj M, Kirkpatrick B, et al. Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 2005;52:83-9.
47. Mata I, Arranz MJ, Staddon S, Lopez-Ilundain JM, Tabares-Seisdedos R, Murray RM. The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. Psychiatr Genet 2006;16:213-6.
48. Gronwall DMA. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977;44:367-73.
49. Minzenberg MJ, Xu K, Mitropoulou V, et al. Catechol-O-methyltransferase Val158Met genotype variation is associated with prefrontal-dependent task performance in schizotypal personality disorder patients and comparison groups. Psychiatr Genet 2006;16:117-24.
50. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007;90:86-96.
51. Weickert TW, Goldberg TE, Mishara A, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004;56:677-82.
52. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004;161:1798-805.
53. Tsai SJ, Hong CJ, Liao DL, Lai IC, Liou YJ. Association study of a functional catechol-O-methyltransferase genetic polymorphism with age of onset, cognitive function, symptomatology and prognosis in chronic schizophrenia. Neuropsychobiology 2004;49:196-200.
54. Stefanis NC, Van Os J, Avramopoulos D, et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol Psychiatry 2004;56:510-5.
55. Bassett AS, Caluseriu O, Weksberg R, Young DA, Chow EW. Catechol-O-methyl Transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome. Biol Psychiatry; 2007 [Epub].
56. Gothelf D, Eliez S, Thompson T, et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 2005;8:1500-2.
57. McIntosh AM, Baig BJ, Hall J, et al. Relationship of Catechol-O- Methyltransferase variants to brain structure and function in a population at high risk of psychosis. Biol Psychiatry 2007;61:1127-34.
58. Ohnishi T, Hashimoto R, Mori T, et al. The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 2006;129(pt 2):399-410.
59. Heinz A, Smolka MN. The effects of catechol O-methyltransferase genotype on brain activation elicited by affective stimuli and cognitive tasks. Rev Neurosci 2006;17:359-67.
60. Blasi G, Mattay VS, Bertolino A, et al. Effect of catechol-O- methyltransferase val158met genotype on attentional control. J Neurosci 2005;25:5038-45.
61. Bertolino A, Caforio G, Petruzzella V, et al. Prefrontal dysfunction in schizophrenia controlling for COMT Val158Met genotype and working memory performance. Psychiatry Res 2006;147:221-6.
62. Drabant EM, Hariri AR, Meyer-Lindenberg A, et al. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry 2006;63:1396-406.
63. Smolka MN, Schumann G, Wrase J, et al. Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 2005;25:836-42.
64. Schurhoff F, Szoke A, Chevalier F, et al. Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele: Am J Med Genet B Neuropsychiatr Genet 2007;144:64-8.
65. Berrettini WH. Genetics of psychiatric disease. Annu Rev Med 2000;51:465-79.
66. McGuffin P, Tandon K, Corsico A. Linkage and association studies of schizophrenia. Curr Psychiatry Rep 2003;5:121-7.
67. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry 2004;9:14-27.
68. Kunugi H, Vallada HP, Sham PC, et al. Catechol-O-methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatr Genet 1997;7:97-101.
69. Wonodi I, Stine OC, Mitchell BD, Buchanan RW, Thaker GK. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;120:47-50.
70. Kremer I, Pinto M, Murad I, et al. Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. Am J Med Genet B Neuropsychiatr Genet 2003;119:35-9.
71. Shifman S, Bronstein M, Sternfeld M, et al. A highly signifi-cant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002;71:1296-302.
72. Li T, Sham PC, Vallada H, Xie T, et al. Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr Genet 1996;6:131-3.
73. Munafò MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry 2005;10:765-70.
74. Bassett AS, Caluseriu O, Weksberg R, Young DA, Chow EW. Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome. Biol Psychiatry; 2007 [Epub].
75. Fan JB, Zhang CS, Gu NF, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 2005;57:139-44.
76. Williams HJ, Glaser B, Williams NM, et al. No association between schizophrenia and polymorphisms in COMT in two large samples. Am J Psychiatry 2005;162:1736-8.
77. Shifman S, Bronstein M, Sternfeld M, et al. COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004;128:61-4.
78. Sanders AR, Rusu I, Duan J, et al. Haplotypic association spanning the 22q11.21 genes COMT and ARVCF with schizophrenia. Mol Psychiatry 2005;10:353-65.
79. Li T, Ball D, Zhao J, et al. Family-based linkage disequilibrium mapping using SNP marker haplotypes: application to a potential locus for schizophrenia at chromosome 22q11. Mol Psychiatry 2000;5:77-84.
80. Chen X, Wang X, O'Neill AF, Walsh D, Kendler KS. Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol Psychiatry 2004;9:962-7.
81. Thapar A, Langley K, Fowler T, et al. 2005. Catechol O-methyltransferase gene variant and birth weight predict early-onset antisocial behavior in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2005;62:1275-8.
82. Cheuk DK, Wong V. Meta-analysis of association between a catechol-O-methyltransferase gene polymorphism and attention deficit hyperactivity disorder. Behav Genet 2006;36:651-9.
83. Enoch MA, Xu K, Ferro E, Harris CR, Goldman D. Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatry Genet 2003;13:33-41.
84. Woo JM, Yoon KS, Choi YH, Oh KS, Lee YS, Yu BH. The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. J Psychiatry Res 2004;38:365-70.
85. Ohara K, Nagai M, Suzuki Y, Ohara K. Low activity allele of catechol-O-methyltransferase gene and Japanese unipolar depression. NeuroReport 1998a;9:1305-8.
86. Karayiorgou M, Sobin C, Blundell ML, et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol Psychiatry 1999;45:1178-89.
87. Papolos DF, Veit S, Faedda GL, Saito T, Lachman HM. Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catecholamine-O-methyltransferase allele. Mol Psychiatry 1998;3:346-9.
88. Gothelf D, Michaelovsky E, Frisch A, et al. Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. Int J Neuropsychopharmacol 2006;31:1-8.
89. Azzam A, Mathews CA. Meta-analysis of the association between the catecholamine-O-methyl-transferase gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2003;123:64-9.
90. Lachman HM, Kelsoe J, Moreno L, Katz S, Papolos DF. Lack of association of catechol-O-methyltransferase (COMT) functional polymorphism in bipolar affective disorder. Psychiatr Genet 1997;7:13-7.
91. Cusin C, Serretti A, Lattuada E, Lilli R, Lorenzi C, Smeraldi E. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. Am J Med Genet 2002;114:380-90.
92. Samochowiec J, Hajduk A, Samochowiec A, et al. Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. Psychiatry Res 2004;128:21-6.
93. Ohara K, Nagai M, Suzuki Y, Ochiai M, Ohara K. No association between anxiety disorders and catechol-O-methyltransferase polymorphism. Psychiatry Res 1998b;80:145-8.
94. Domschke K, Freitag CM, Kuhlenbaumer G, et al. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. Int J Neuropsychopharmacol 2004;7:183-8.
95. Shprintzen RJ. Velo-cardio-facial syndrome: a distinctive behavioral phenotype. Ment Retard Dev Disabil Res Rev 2000;6:142-7.
96. Bassett AS, Chow EWC. 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol Psychiatry 1999;46:882-91.
97. Bassett AS, Hodgkinson K, Chow EWC, Correia S, Scutt LE, Weksberg R. 22q11 deletion syndrome in adults with schizophrenia. Am J Med Genet 1998;81:328-37.
98. Gothelf D, Frisch A, Munitz H, et al. Velocardiofacial manifestations and microdeletions in schizophrenic inpatients. Am J Med Genet 1997;72:455-61.
99. Papolos DF, Faedda GL, Veit S, et al. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? Am J Psychiatry 1996;153:1541-7.
100. Yan W, Jacobsen LK, Kransnewich DM, et al. Chromosome 22q11.2 interstitial deletions among childhood-onset schizophrenics and "multidimensionally impaired." Am JMed Genet 1998;81:41-3.
101. Murphy KC, Jones LA, Owen MJ High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999;56: 940-5.
102. Pulver AE, Nestadt G, Goldberg R, et al. Psychotic illness in patients diagnosed with velo-cardio-facial-syndrome. J Nerv Ment Dis 1994;182:476-8.
103. Horowitz A, Shifman S, Rivlin N, Pisante A, Darvasi A. A survey of the 22q11 microdeletion in a large cohort of schizophrenia patients. Schizophr Res 2005;73:263-7.
104. Karayiorgou M, Morris MA, Morrow B, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 1995;92:7612-6.
105. Usiskin SI, Nicolson R, Krasnewich DM, Yan W, Lenane M, Wudarsky M. Velocardialfacial syndrome in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1999;38:1536-43.
106. Henry JC, van Amelsvoort TV, Morris RG, Owen MJ, Murphy DG, Murphy KC. An investigation of the neuropsychological profile in adults with velo-cardio-facial syndrome. Neuropsychologia 2002;40:471-8.
107. van Amelsvoort T, Henry J, Morris R, et al. Cognitive deficits associated with schizophrenia in velo-cardio-facial syndrome. Schizophr Res 2004;70:223-32.
108. Lewandowski KE, Shashi V, Berry MN, Kwapil TR. Schizophrenic-like neurocognitive deficits in children and adolescents with 22q11 deletion syndrome. Am J Med Genet B Neuropsychiatr Genet 2007;144:27-36.
109. Bearden CE, Woodin MF, Wang PP, et al. The neurocognitive phenotype of the 22q11.2 deletion syndrome: selective deficit in visual-spatial memory. J Clin Exp Neuropsychol 2001;23:447-64.
110. Swillen A, Vogels A, Devriendt K, Fryns JP. Chromosome 22q11 deletion syndrome: update and review of the clinical features, cognitive-behavioral spectrum, and psychiatric complications. Am J Med Genet 2000;97:128-35.
111. Gerdes M, Solot C, Wang PP, et al. Cognitive and behavior profile of preschool children with chromosome 22q11.2 deletion. Am J Med Genet 1999;85:127-33.
112. Shashi V, Keshavan MS, Howard TD, et al. Cognitive correlates of a functional COMT polymorphism in children with 22q11.2 deletion syndrome. Clin Genet 2006;69:234-8.
113. Bearden CE, Rosso IM, Hollister JM, Sanchez LE, Hadley T, Cannon TD. A prospective cohort study of childhood behavioral deviance and language abnormalities as predictors of adult schizophrenia. Schizophr Bull 2000;26:395-410.
114. Cannon M, Jones P, Gilvarry C, et al. Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Am J Psychiatry 1997;154:1544-50.
115. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994;344:1398-402.
116. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45.
117. Cannon TD. The inheritance of intermediate phenotypes for schizophrenia. Curr Opin Psychiatry 2005;18:135-40.
118. Berrettini WH. Genetic bases for endophenotypes in psychiatric disorders. Dialogues Clin Neurosci 2005;7:95-101.
119. Nicodemus KK, Kolachana BS, Vakkalanka R, et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet 2007;120:889-906.
120. Smolka MN, Buhler M, Schumann G, et al. Gene-gene effects on central processing of aversive stimuli. Mol Psychiatry 2007 [Epub].
121. Funke B, Malhotra AK, Finn CT, et al. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct 2005;18:1-19.
122. Barnett JH, Heron J, Ring SM, et al. Gender-specific effects of the catechol-O-methyltransferase Val108/158Met polymorphism on cognitive function in children. Am J Psychiatry 2007;164:142-9.
123. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117-27.
124. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW. Role of genotype in the cycle of violence in maltreated children. Science 2002;297:851-4.
125. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-9.
126. Foley DL, Eaves LJ, Wormley B, et al. Childhood adversity, monoamine oxidase A genotype, and risk for conduct disorder. Arch Gen Psychiatry 2004;61:738-44.
127. Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 2005;62:529-35.
128. Luchins D. The dopamine hypothesis of schizophrenia. A critical analysis. Neuropsychobiology 1975;1:365-78.